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Introduction
Adult attention-deficit/hyperactivity disorder (ADHD) patients treated with methylphenidate (MPH) commonly use or misuse ethanol (Levin and Kieber 1995; Darredeau et al., 2007) . In addition, the diversion and abuse of MPH has been on the rise (Scharman et al., 2007) and many, if not most, MPH abusers report co-abuse with ethanol (Teter et al., 2003; Barrett et al., 2005; Darredeau et al., 2007; Novak et al., 2007; Wilens et al., 2008) . In a previous drug interaction study using normal volunteers, ethanol was found to significantly increase positive subjective responses to dl-MPH (Patrick et al., 2007) , as consistent with the illicit popularity of this drug combination.
The influence of ethanol on dl-MPH pharmacokinetics (Patrick et al., 2007) includes: (1) an increase in the rate of d-MPH absorption which has implications for heightened abuse liability (Volkow et al., 2003; Spencer et al., 2006) ; (2) an increase in the mean maximum plasma concentration (C max ) of d-MPH where threshold brain concentrations associated with reinforcing effects may be reached (Volkow et al., 2003); and (3) an increase in the overall plasma exposure to d-MPH [area under the curve (AUC)]. In addition to these ethanolmediated influences on the psychoactive d-MPH isomer (Srinivas et al., 1992 , Aoyama et al., 1994 , the inactive l-MPH isomer (Markowitz and Patrick, 2008) serves as the enantioselective transesterification substrate (Patrick et al., 2007; Zhu et al., 2011) for carboxylesterase 1 (CES1); l-MPH combines with ethanol to yield the inactive metabolite l-ethylphenidate (EPH; Fig.1 ) (Patrick et al., 2005;  This article has not been copyedited and formatted. The final version may differ from this version. , 2007) . This biotransformation product can serve as a biomarker for concomitant dl-MPH-ethanol exposure (Markowitz et al., 1999) analogous to the detection of the transesterification metabolite cocaethylene (ethylcocaine) evidencing cocaine-ethanol co-abuse (Herbst et al., 2011) .
Over 80% of an oral dose of dl-MPH can be recovered in the urine (Redalieu et al., 1982) as the inactive (Patrick et al., 1981) hydrolysis metabolite ritalinic acid ( Fig. 1) . Approximately 1% is excreted unchanged (LeVasseur et al., 2008) .
Both the hydrolysis of dl-MPH to ritalinic acid and the transesterification with ethanol to yield l-EPH are primarily catalyzed by hepatic CES1 (Bourland et al., 1997; Sun et al., 2004; Zhu et al., 2008; 2009) . Pre-systemic hydrolysis of oral dl-MPH results in the relatively low oral bioavailability of 25% for the therapeutic d-MPH isomer (Srinivas et al., 1992; Aoyama et al., 1994) . However, due to the pronounced enantioselectivity of CES1 only 2-5% (Srinivas et al., 1993; Modi et al., 2000) or less (Patrick, et al., 2007) of the inactive l-MPH isomer (Markowitz and Patrick 2008) reaches the systemic circulation, except in the circumstance of a CES1 null allele (Patrick et al., 2007; LeVasseur et al., 2008; Zhu et al., 2008) .
The single isomer d-MPH became a treatment option for ADHD in 2002.
Head-to-head efficacy comparisons of immediate-release d-MPH versus dl-MPH in ADHD children, using twice-daily regimens with d-MPH administered at half the mg/kg dose of dl-MPH, found comparable efficacy over the course of a typical school day (Wigal et al., 2004) . The present study extends the This article has not been copyedited and formatted. The final version may differ from this version. We explored the hypothesis that the ethanol-induced increase in d-MPH bioavailability following dl-MPH administration will be significantly reduced upon substituting enantiopure d-MPH for dl-MPH, the reasoning being that removal from the formulation of the more rapidly metabolized CES1 substrate l-MPH will avoid competitive inhibition of CES1 during d-MPH absorption. In the following normal volunteer study, 12 men and 12 women were administered dl-MPH (0.3 mg/kg) or d-MPH (0.15 mg/kg) with or without ethanol (0.6 g/kg) 0.5 h later in a randomized, 4-way cross-over design. Serial blood samples were drawn for enantiospecific pharmacokinetic analysis of plasma MPH and EPH, as well for blood ethanol determinations. Periodic subjective effects utilized visual analog scale (VAS) questionnaires and hemodynamic effects were recorded.
This article has not been copyedited and formatted. The final version may differ from this version. were healthy as assessed by medical history, physical examination, 12-lead electrocardiogram, and routine laboratory tests. All subjects were within 15% of ideal body weight, were non-smokers and were asked to abstain from the use of caffeine containing beverages beginning at 7:30 p.m. the evening before and continuing through each active study day.
Study design. All subjects were admitted to the clinic on the morning of each active study day. One hour prior to dosing, the subjects received a light breakfast of a plain bagel (36 g total: fat 1 g, carbohydrate 29 g, protein 6 g) with cream cheese (30 g total: fat 9.2 g, protein 4.4 g, carbohydrate 0.03 g) and skim milk (240 ml total: fat 9.2 g, carbohydrate 11.5 g, protein 8.4 g), finished within 15 min.
Then an indwelling venous catheter was placed in each subject's arm for serial blood sampling. MPH was administered with 240 ml of water. Ethanol or nonethanol orange juice drinks were consumed 0.5 h after MPH dosing. The ethanol drink was administered as 0.6 g/kg ethanol (0.66 ml/kg 95% ethanol) in 180 ml of orange juice and 60 ml of soda water, with water added to give a total volume of 450 ml. On alcohol free treatments, the alcohol volume was replaced with water.
This article has not been copyedited and formatted. The final version may differ from this version. Pharmaceuticals, Summit, NJ), and the 2.5 mg tablets cut to the nearest 1.25 mg using a tablet cutter as appropriate.
A total of 12 blood samples were taken over each active study period from the indwelling venous catheter. These blood collection times correspond to 0, 0.5, 1, 25, 2.25, 3.25, 4.25, 5.25 , and 11 h after MPH dosing. The subscales allowed rating of the degree to which the subject was experiencing each effect by making a vertical mark on a graduated (0-10) solid line ranging in drug effect from "not at all" (0) to "extremely" (10).
This article has not been copyedited and formatted. The final version may differ from this version. 12 compared using analysis of variance (ANOVA) with Treatment (A,B,C,D) as a between (repeated measures) factor and sex as a between subjects factor using the Latin square design to take into account sequence (carry-over) effect as described by Winer (1962) . The level of significance was set at P= 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. completed the entire protocol. Treatment emergent sinus tachycardia resulted in one subject being removed from the study. Another subject withdraw due to a headache, nausea and vomiting. Dropped subjects were replaced. Nine occurrences of headaches were reported and were treated with ibuprofen (400 mg administered at the earliest 3.5 h following the MPH dose thus after d-MPH T max and after time to peak subjective effects). No subject had any clinically significant findings on post-study "exit" laboratory tests. Table 1 , while the statistical comparisons are given in Table 2 Table 2 shows the pharmacokinetic statistical comparisons of the treatments.
Influence of ethanol on d-MPH pharmacokinetics: dl-MPH versus d-MPH.
For the two dl-MPH treatments, ethanol significantly increased the C max by 22% Enantioselective transesterification of l-MPH to l-EPH. Metabolic transesterification of MPH to EPH was enantioselective in the formation of l-EPH (Fig. 1) ; and was only detected in the dl-MPH-ethanol treatments. l-EPH reached a mean Cmax of 0.45 ng/ml with a T max of 2 h (Fig. 3) . No significant sex difference was found in the extent of l-EPH formation. The highest individual concentration of plasma l-EPH was 1.28 ng/ml. No d-EPH was detected in any sample owing to the very limited extent to which d-MPH serves as a transesterification substrate and our lower limit of detection being 0.05 ng/ml of plasma (see Zhu et al., 2011 for d-EPH findings using increased sensitivity).
Subjective effects. Table 3 summarizes the maximum VAS subscale responses from "any drug effect" in general, as well as those more directly serving as surrogates for abuse liability, i.e., the positive subjective effects of "high", "good", "like" and "stimulated". These maximum effects occurred either at 0.75 h following MPH or more frequently at 1.25 h post-MPH. Other than "intoxicated", the negative effects were generally below the effect scale of 1. In
This article has not been copyedited and formatted. The final version may differ from this version. The baseline values did not differ significantly from the 10 h questionnaires and baseline values were subtracted from the post-dosing responses. There were no statistically different sex differences in subjective effects though there was a trend toward greater effects in men than in women.
Hemodynamic effects. Concomitant ethanol significantly elevated heart rates in both the dl-MPH and d-MPH drug combination treatments (Fig. 7) . There was a trend toward a greater effect on heart rate for the dl-MPH-ethanol treatment than for the d-MPH-ethanol treatment. The greatest time point increase in heart rate for any treatment was at the 0.75 h reading for the dl-MPH-ethanol treatment (14 beats/min); the time corresponding to completion of the ethanol drink. The mean diastolic and systolic pressures were elevated more in the two ethanol combination treatments than in the MPH only treatments but these difference did not reach statistical significance.
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The time interval of 0.5-2 h was of special interest in this study because it brackets the time from when subjects first began ethanol consumption until the approximate end of the absorption phases for d-MPH (Fig. 2) , l-MPH ( Within the 0.5-1.0 h period, one VAS questionnaire was administered (0.75 h following dl-MPH; Table 3 ). The responses to the VAS subscales "any drug effect" and the positive subjective effects "high", "good", "like" and "stimulated"
were all significantly greater at 0.75 h (immediately after ethanol consumption)
for the racemic dl-MPH-ethanol combination compared to dl-MPH given alone.
With the pure d-MPH-ethanol treatment, only "high" was significantly greater than (Table 3) .
Correlations between an increase in d-MPH absorption rate and enhanced positive subjective effects have served as surrogates for abuse liability.
Increasing the rate of d-MPH absorption (Kollins et al., 1998; Spencer et al. 2012) , and the subsequent rate of delivery to the central nervous system (Roberts et al., 1993; 1995; Hedaya et al., 1996; Parker et al., 2010) .
The significant elevation of heart rate upon combining ethanol with either dl-MPH or d-MPH (Fig.7) is consistent with the resulting increase in exposure to the pressor agent d-MPH. In addition, this cardiovascular response may be attributable to additive catecholaminergic influences of MPH and ethanol. The dose of ethanol used in the present study has been reported to elevate heart rate by 5.7 beats/min (Spaak et al., 2008) . Similarly, combining ethanol with cocaine has been shown to significantly elevate heart rate in humans compared to cocaine alone (Herbst et al., 2011) .
The pharmacokinetics of the dl-MPH and d-MPH treatments without ethanol provides evidence (Table 2) This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
